New England Journal of Medicine· 2018Q1· Clinical trial

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon et al.

6,343citations
Q1SCImago
2018year

Short summary

In patients with type 2 diabetes, dapagliflozin did not significantly reduce major adverse cardiovascular events (MACE) but did lower the rate of cardiovascular death or hospitalization for heart failure by 17% compared to placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine